Some anticancer therapies, such as those targeting erbB2 (an EGF receptor family member) with monoclonal antibodies, might be considered for lung fibrosis therapy to reduce mesenchymal cell survival and resolve a fibrotic reaction. This evidence concerns the gene ERBB2 and pulmonary fibrosis.